Etoposide - Evolve Oncology
Alternative Names: BIO 121Latest Information Update: 16 Jan 2022
Price :
$50 *
At a glance
- Originator Evolve Oncology
- Class Antineoplastics; Tetrahydronaphthalenes
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer in USA
- 19 Sep 2005 Phase-I clinical trials in Cancer in USA (unspecified route)